Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer

Tomas Pascual; María Apellániz-Ruiz; Cristina Pernaut; Cecilia Cueto-Felgueroso; Pablo Villalba; Carlos Álvarez; Luis Manso; Lucia Inglada-Pérez; Mercedes Robledo; Cristina Rodríguez-Antona; Eva Ciruelos

doi:10.1371/journal.pone.0180192

Loading metrics

Open Access

Peer-reviewed

Research Article

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer

Tomas Pascual ,

Contributed equally to this work with: Tomas Pascual, María Apellániz-Ruiz

Current address: Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain.

Affiliation Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain
⨯
María Apellániz-Ruiz ,

Contributed equally to this work with: Tomas Pascual, María Apellániz-Ruiz

Affiliation Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
⨯
Cristina Pernaut,

Affiliation Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain
⨯
Cecilia Cueto-Felgueroso,

Affiliation Biochemistry Department, 12 de Octubre University Hospital, Madrid, Spain
⨯
Pablo Villalba,

Affiliation Biochemistry Department, 12 de Octubre University Hospital, Madrid, Spain
⨯
Carlos Álvarez,

Affiliation Biochemistry Department, 12 de Octubre University Hospital, Madrid, Spain
⨯
Luis Manso,

Affiliation Biochemistry Department, 12 de Octubre University Hospital, Madrid, Spain
⨯
Lucia Inglada-Pérez,

Affiliations Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
⨯
Mercedes Robledo,

Affiliations Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
⨯
Cristina Rodríguez-Antona,

Affiliations Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
⨯
Eva Ciruelos

* E-mail: eva.ciruelos@gmail.com

Affiliation Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain
⨯

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer

Tomas Pascual,
María Apellániz-Ruiz,
Cristina Pernaut,
Cecilia Cueto-Felgueroso,
Pablo Villalba,
Carlos Álvarez,
Luis Manso,
Lucia Inglada-Pérez,
Mercedes Robledo,
Cristina Rodríguez-Antona

Published: July 20, 2017
https://doi.org/10.1371/journal.pone.0180192

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Toxicity
Is the Subject Area "Toxicity" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.
Endocrine therapy
Is the Subject Area "Endocrine therapy" applicable to this article?

Thanks for your feedback.
Single nucleotide polymorphisms
Is the Subject Area "Single nucleotide polymorphisms" applicable to this article?

Thanks for your feedback.
Pharmacokinetics
Is the Subject Area "Pharmacokinetics" applicable to this article?

Thanks for your feedback.
Hyperglycemia
Is the Subject Area "Hyperglycemia" applicable to this article?

Thanks for your feedback.